<DOC>
	<DOCNO>NCT01969435</DOCNO>
	<brief_summary>Phase II study conduct confirm safety efficacy high-dose Melphalan HCl Injection ( Propylene Glycol-Free ) include BEAM regimen myeloablative condition lymphoma patient undergoing ASCT</brief_summary>
	<brief_title>Study Melphalan HCl Injection ( Propylene Glycol-free ) , Carmustine , Etoposide , Cytarabine ( BEAM Regimen ) Autologous Stem Cell Transplantation Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Diagnosis Hodgkin lymphoma nonHodgkin lymphoma . Eligible autologous stem cell transplantation . 18 75 year age time enrollment . Adequate autologous graft , define unmanipulated , cryopreserved , peripheral blood stem cell graft contain least 2 x 10^6 CD34+ cells/kg base patient body weight ECOG performance status ≤ 2 Normal organ function define : Creatinine clearance &gt; 40 ml/min Total bilirubin ≤2.0 x IULN AST ( SGOT ) /ALT ( SGPT ) ≤ 3.0 x IULN LVEF &gt; 40 % ( ECHO MUGA ) FEV1 &gt; 50 % predict DLCO &gt; = 50 % predicted Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Able understand willing sign IRB approve write informed consent document . A history malignancy ≤ 5 year previous exception basal cell squamous cell carcinoma skin treat local resection carcinoma situ cervix . Currently receive experimental therapy receive experimental therapy within 4 week prior enrollment . A history allergic reaction attribute compound similar chemical biologic composition melphalan HCl injection ( propylene glycolfree ) , Captisol , agent use study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , unstable cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant and/or breastfeed woman . Women childbearing potential must negative serum pregnancy test within 14 day study entry . Known HIVpositivity . These patient exclude potential pharmacokinetic interaction study regimen antiretroviral therapy patient increase risk lethal infection treat marrowsuppressive therapy . .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>